Featured Reports

• DW Index Crash 3-15-16
• SCN NIRPS Pose Bank Risk 3-15-16

About Michael Markowski

Michael Markowski has been a visionary analyst since 1978. Throughout his 37 years in the Capital Markets he has endeavored to discover the Financial Statement metrics which drive the valuations of assets.

Markowski began conducting visionary research during his training at Merrill Lynch. It led to GEICO becoming the very first stock recommendation he made to his clients. The auto insurance company was subsequently acquired by Warren Buffet’s Berkshire Hathway for a 900% gain. The research Markowski conducted (while employed at Donaldson Lufkin & Jenrette in 1984) on 250 public companies which had significantly outperformed the stock market enabled him to conclude that the companies had a common denominator enabling their shares to outperform the overall market.

After Enron mysteriously collapsed into bankruptcy with its share price falling to pennies within six months of having a price of over $50, Mr. Markowski conducted a post mortem (financial) autopsy to see if he could determine what caused its financial collapse. Enron’s Financial Statement anomaly, discovered by Markowski, inspired him to develop a diagnostic algorithm to identify this type of anomaly. He then launched a website which investors use to diagnose and monitor their holdings for this very anomaly that had stricken hundreds of public companies, including Lehman Brothers, over the last 10 years.

Markowski’s most valuable research to date is his most recent research on Crowdfunding and the impact that it’s going to have on the share prices of those companies which are already in position to benefit from Crowdfunding. This research provides a roadmap for investors to generate potentially 10 to 100 times on their investment from a diversified portfolio by the end of the decade.

To learn more please visit http://www.michaelmarkowski.net/research.php

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.

The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.

The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells.

The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.

Immune is headquartered in the U.S., with its primary research and development facilities in Israel.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and Zanaflex tablets for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

The company also markets Ampyra as Fampyra in Europe, Asia, and the Americas. It is also involved in developing CVT-301, which is in Phase III clinical trial for the treatment of OFF episodes in Parkinson’s disease; Dalfampridine that is in Phase III clinical trial for the treatment of chronic post-stroke deficits; Neuregulin Program, which is in Phase Ib clinical trial for the treatment of heart failure; CVT-427 that is in pre-clinical development for the treatment of migraines; Remyelinating Antibodies Program, which is in Phase I clinical trial for the treatment of MS; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury, as well as developing Plumiaz, a proprietary nasal spray formulation of diazepam for the treatment of people with epilepsy. The company has a collaboration agreement with Biogen Idec International GmbH for the development and commercialization of products containing aminopyridines. The company was founded in 1995 and is headquartered in Ardsley, New York.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, and therapeutics and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead program, ImmunoPulse IL-12, is in Phase II development for various indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the company’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostics and therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, and ophthalmological disorders. The company’s diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation.

Its therapeutic products in development comprise Eltoprazine, a small molecule drug that is in Phase II clinical trials for the treatment of Parkinson’s disease Levadopa-Induced Dyskinesia and adult attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including iretinitis pigmentosa, Parkinson’s disease, cardiac ischemia, and stroke.

It is also developing NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University to develop its full thickness skin replacement product. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.

Activist investor Carl Icahn's Icahn Enterprises offered Monday to buy all outstanding common stock of Pep Boys-Manny, Moe and Jack for $15.50 per share in cash. The proposal comes after Icahn reported Friday a 12.12 percent stake in the auto services and retail company. Pep Boys previously reached a deal in October to be acquired by Bridgestone for $15 per share, or $835 million.

"We believe our proposal is clearly superior to the $15.00 per share Bridgestone transaction and that our financial wherewithal to close expeditiously is indisputable," Icahn Enterprises wrote in a letter to Pep Boys.

Pep Boys shares traded about 2 percent higher on Monday afternoon.

The Icahn letter added that the proposal would not be subject to "any due diligence, financing or antitrust conditions."

In a Securities and Exchange Commission filing last week, Icahn said Pep Boys' auto parts segment "presents an excellent synergistic acquisition opportunity" for Auto Plus, which is owned by Icahn Enterprises. The billionaire investor's representatives have held talks with Pep Boys and "various parties" about possible transactions involving its retail arm.